The American pharmaceutical company Johnson & Johnson (J&J) expects to have its corona vaccine ready in the spring of next year. In March or April, the drug could be used for vaccination.
Subsidiary Janssen is technologically advancing the J&J vaccine in Leiden. According to Stoffels, a large clinical study with 40,000 people in North America, South America and Africa is underway, and an attempt is made to get results in January.
He hopes to get approval in the United States in early March and then reasonably soon in Europe. “By the end of March or April, we will be able to vaccinate on a large scale.”
Stoffels is Chief Scientific Officer at J&J or head of medical research in the pharmaceutical industry. He went on to say that it was not painful that the Pfizer-BioNTech duo was earlier in bringing a vaccine to market than J&J.
“We need to produce 4 to 8 billion vaccines worldwide. dose vaccine “. That is important to be able to vaccinate on a large scale.” This is because two doses are required with Pfizer-BioNTech.
Stoffels also points out that J & J’s vaccine can be stored more easily. “The Pfizer vaccine is distributed at minus 70 degrees, and our vaccine is kept between 2 and 8 degrees.
That is in the refrigerator, so to speak more easily distributed around the world. That will have a major impact on vaccination, also in developing countries, for example. “
